AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis ; volume:14 ; number:1 ; day:1 ; month:11 ; year:2024 ; pages:1-16 ; date:12.2024
Scientific reports ; 14, Heft 1 (1.11.2024), 1-16, 12.2024

Creator
Duan, Rui
Shi, Liang
Deng, Yang
Wu, Jiang
Wang, Shiyao
Peng, Qiang
Li, Zhongyuan
Xu, Zhaohan
Wang, Feng
Xue, Xue
Gao, Qing
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-024-76058-w
URN
urn:nbn:de:101:1-2501212127108.186323063687
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Duan, Rui
  • Shi, Liang
  • Deng, Yang
  • Wu, Jiang
  • Wang, Shiyao
  • Peng, Qiang
  • Li, Zhongyuan
  • Xu, Zhaohan
  • Wang, Feng
  • Xue, Xue
  • Gao, Qing
  • SpringerLink (Online service)

Other Objects (12)

Models of α-synuclein aggregation in Parkinson’s disease

Models of α-synuclein aggregation in Parkinson’s disease

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Initiation and progression of α-synuclein pathology in Parkinson’s disease

Initiation and progression of α-synuclein pathology in Parkinson’s disease

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson’s disease therapy

Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson’s disease therapy

Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease

Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease

Related objects